

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 17, 2022

Richard Peters, M.D. Chief Executive Officer Yumanity Therapeutics, Inc. 40 Guest Street, Suite 4410 Boston, MA 02135

Re: Yumanity Therapeutics, Inc.

Form S-4/A

Exhibit Nos. 10.6, 10.7, 10.41, 10.43, 10.45, 10.46, 10.47, 10.48, 10.49,

10.50, 10.51 and 10.52 Filed November 4, 2022 File No. 333-267127

Dear Dr. Richard Peters:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance